Ge
Genkyotex (Calliditas)
Geneva CHFounded 200130 employees
Private CapbiotechAcquiredHepatology
Platform: Setanaxib NOX
Market Cap
N/A
All Drugs
3
Clinical Trials
4
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Gelisacituzumab | GEN-1614 | Phase 2 | 2 | C5 | RSV | ||
| Voxacapivasertib | GEN-7578 | Preclinical | 1 | SMN2 | ET | ||
| GEN-516 | GEN-516 | Phase 2/3 | 1 | PLK4 | NBHCC |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (4)